Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115, USA.
Hypertension. 2010 Feb;55(2):241-8. doi: 10.1161/HYPERTENSIONAHA.109.138529. Epub 2009 Dec 7.
Diastolic dysfunction may precede development of heart failure in hypertensive patients. We randomized 228 patients with uncontrolled hypertension, preserved ejection fraction, and diastolic dysfunction to 2 targeted treatment strategies: intensive, with a systolic blood pressure target of <130 mm Hg, or standard, with a systolic blood pressure target of <140 mm Hg, using a combination of valsartan, either 160 or 320 mg, plus amlodipine, either 5 or 10 mg, with other antihypertensive medications as needed. Echocardiographic assessment of diastolic function was performed at baseline and after 24 weeks in a prospective, open-label, blinded end point design. Blood pressure was reduced significantly in both groups, from 161.2+/-13.9/90.1+/-12.0 to 130.8+/-12.3/74.9+/-9.1 mm Hg (P<0.0001) in the intensive arm and from 162.1+/-13.2/93.7+/-12.2 to 137.0+/-12.9/79.6+/-11.0 mm Hg (P<0.0001) in the standard arm (P<0.003 for between-group comparisons). Myocardial relaxation velocity improved from 7.6+/-1.1 to 9.2+/-1.7 cm/s (Delta 1.54+/-1.4 cm/s; P<0.0001) in the intensive arm and from 7.5+/-1.3 to 9.0+/-1.9 cm/s (Delta 1.48+/-1.6 cm/s; P<0.0001) in the standard arm, with no difference between the 2 strategies in the achieved improvement (P=0.58). The degree of improvement in annular relaxation velocity was associated with the extent of systolic blood pressure reduction, and patients with the lowest achieved systolic blood pressure had the highest final diastolic relaxation velocities.
舒张功能障碍可能先于高血压患者心力衰竭的发展。我们将 228 名未控制的高血压、射血分数保留和舒张功能障碍患者随机分为 2 种靶向治疗策略:强化治疗,收缩压目标<130mmHg;标准治疗,收缩压目标<140mmHg,使用缬沙坦(160 或 320mg)联合氨氯地平(5 或 10mg),必要时加用其他降压药物。在一项前瞻性、开放标签、盲终点设计的研究中,于基线和 24 周时进行舒张功能的超声心动图评估。两组的血压均显著降低,强化组从 161.2+/-13.9/90.1+/-12.0 降至 130.8+/-12.3/74.9+/-9.1mmHg(P<0.0001),标准组从 162.1+/-13.2/93.7+/-12.2 降至 137.0+/-12.9/79.6+/-11.0mmHg(P<0.0001)(两组间比较 P<0.003)。心肌弛豫速度从 7.6+/-1.1 提高到 9.2+/-1.7cm/s(Delta 1.54+/-1.4cm/s;P<0.0001),强化组从 7.5+/-1.3 提高到 9.0+/-1.9cm/s(Delta 1.48+/-1.6cm/s;P<0.0001),两种治疗策略在获得的改善方面没有差异(P=0.58)。环壁松弛速度的改善程度与收缩压降低的程度相关,收缩压降低幅度最大的患者最终舒张松弛速度最高。